Precision oncology market seen doubling to $230.4B by 2032

The global precision oncology market is projected to rise from about $118.8 billion in 2025 to $230.40 billion by 2032, driven by genomics, targeted therapies and AI tools. The outlook underscores how personalized cancer care is moving deeper into routine diagnosis and treatment worldwide. Why it matters: - Precision oncology is shifting cancer care toward treatments matched to a patient’s genetics, tumor profile and molecular biomarkers. - The market’s projected climb to $230.40 billion by 2032 signals sustained demand for targeted therapies, genomic testing and biomarker-based diagnostics. - The growth reflects a broader move away from one-size-fits-all cancer treatment and toward approaches designed to improve outcomes and reduce adverse effects. What happened: - Maximize Market Research projected the global precision oncology market at about $118.8 billion in 2025. - The firm forecast a 9.9% compound annual growth rate through 2032. - The market is expected to reach $230.40 billion by 2032. - The forecast was released June 10, 2026. - The release was issued from Austin, Texas. - A sample report is available here . - The full report is available here . The details: - Precision oncology uses genetic profiling, tumor characteristics and molecular biomarkers to guide treatment selection. - Rising cancer incidence across breast, lung, colorectal, prostate and hematologic cancers is pushing demand for more personalized options. - Governments and healthcare organizations are increasing cancer research spending focused on earlier diagnosis and better therapeutic outcomes. - Next-generation sequencing is expanding as falling sequencing costs make comprehensive tumor profiling more accessible. - Targeted therapies and immunotherapies are gaining share because they can act on cancer-linked genetic abnormalities. - Artificial intelligence and machine learning are being used in oncology research for drug discovery, patient stratification and treatment planning. - Recent market activity includes expanded genomic testing portfolios, new companion diagnostics and additional targeted therapy approvals. - Liquid biopsy is emerging as a non-invasive diagnostic tool that detects tumor-derived genetic material through blood samples. - Molecular tumor boards and genomic profiling services are becoming part of routine clinical workflows. - By product type, diagnostics, therapeutics, companion diagnostics, genomic testing solutions and biomarker discovery tools are the key categories. - Diagnostics and genomic testing solutions hold a significant share because of demand for molecular profiling and early cancer detection. - By technology, next-generation sequencing remains the dominant segment. - Polymerase chain reaction, immunohistochemistry, in situ hybridization and microarray technology also remain in use. - By cancer type, lung and breast cancer lead the market. - By end user, hospitals and cancer centers are major buyers as they add genomic testing to clinical workflows. - Emerging trends include multi-omics, decentralized clinical trials and cloud-based genomic data management. - CRISPR-based gene editing, AI-driven predictive analytics and personalized cancer vaccines are among the innovation areas the report highlights. Between the lines: - The market story is not just about drug development; it is also about the diagnostics and data infrastructure needed to match therapies to the right patients. - AI, cloud systems and multi-omics suggest precision oncology is becoming a data-intensive specialty, not only a pharmaceutical one. - Liquid biopsy and decentralized trials point to a push for faster, less invasive and more distributed cancer research. What’s next: - The market is expected to keep expanding as genomic medicine, AI applications and targeted therapies spread across care settings. - More hospitals, diagnostic labs and specialty cancer centers are likely to build genomic testing into standard workflows. - Regulatory support for precision medicine and ongoing clinical trials for personalized cancer vaccines could add momentum. - Maximize Market Research said the report can be customized for client needs. The bottom line: - Precision oncology is moving from niche science to core cancer-care infrastructure, and the market forecast suggests that shift will accelerate through 2032.